List of Excipients in Branded Drug CORTEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CORTEF	hydrocortisone	0009-0012	CALCIUM STEARATE
Pharmacia & Upjohn Company LLC	CORTEF	hydrocortisone	0009-0012	LACTOSE
Pharmacia & Upjohn Company LLC	CORTEF	hydrocortisone	0009-0012	MINERAL OIL
Pharmacia & Upjohn Company LLC	CORTEF	hydrocortisone	0009-0012	SORBIC ACID
Pharmacia & Upjohn Company LLC	CORTEF	hydrocortisone	0009-0012	STARCH, CORN
Pharmacia & Upjohn Company LLC	CORTEF	hydrocortisone	0009-0012	SUCROSE
REMEDYREPACK INC	CORTEF	hydrocortisone	70518-3275	CALCIUM STEARATE

CORTEF Excipient Strategy, Patent Position, and Commercial Opportunities for Hydrocortisone Tablets

Last updated: August 2, 2026

CORTEF is an immediate-release oral hydrocortisone tablet marketed for corticosteroid replacement and anti-inflammatory indications. Its excipient system is simple and inexpensive: lactose, mineral oil, sorbic acid, starch, and sucrose are identified in FDA labeling. The principal commercial opportunity is not protection of the historical CORTEF formulation. It is development of differentiated hydrocortisone products that improve pediatric dosing, excipient tolerability, stability, palatability, adherence, or supply reliability.

The active ingredient, hydrocortisone, is a long-established corticosteroid with no meaningful remaining composition-of-matter exclusivity. Generic entry risk is therefore high, while commercial differentiation depends on formulation execution, regulatory positioning, manufacturing reliability, and distribution.

What is CORTEF and which excipients does it contain?

CORTEF is an oral hydrocortisone tablet available historically in 5 mg, 10 mg, and 20 mg strengths. Hydrocortisone is chemically identical to cortisol and is used for glucocorticoid replacement in adrenal insufficiency, congenital adrenal hyperplasia, and other corticosteroid-responsive conditions.

FDA labeling identifies the following inactive ingredients for CORTEF tablets:

Excipient	Likely formulation function
Lactose	Diluent and tablet-volume agent
Mineral oil	Processing aid and lubricant
Sorbic acid	Preservative or antimicrobial protection
Starch	Binder, disintegrant, or filler
Sucrose	Diluent and taste-modifying component

The precise quantitative composition, manufacturing process parameters, particle-size specifications, and compression conditions are generally not disclosed in public labeling. The listed excipients indicate a conventional compressed-tablet platform rather than an extended-release, enteric-coated, osmotic, or multiparticulate delivery system. (U.S. Food and Drug Administration [FDA], n.d.-a)

What formulation characteristics define the CORTEF product?

CORTEF's formulation profile has several commercial implications:

• It uses low-cost, widely available excipients.
• It is suitable for conventional high-volume tablet manufacture.
• Lactose and sucrose create avoidable restrictions for some patients.
• The low hydrocortisone dose creates content-uniformity and splitting challenges.
• Sorbic acid and mineral oil may complicate efforts to market a simplified excipient profile.
• The formulation is not optimized for infants or young children who cannot reliably swallow tablets.

Hydrocortisone has a narrow dosing range in replacement therapy. Small dose errors can have clinical consequences, particularly in pediatric adrenal insufficiency. This makes tablet uniformity, score-line performance, and dose flexibility more commercially relevant than the low cost of the active ingredient.

What excipient strategy is best for a CORTEF competitor?

A successful competitor should use a platform strategy rather than reproduce the historical excipient list without modification. Four formulation paths have the strongest commercial logic.

Lactose-free and sucrose-free immediate-release tablets

A lactose-free product could address patients with lactose intolerance, excipient sensitivity, or dietary restrictions. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, or partially pregelatinized starch could replace lactose, subject to compatibility and dissolution testing.

Sucrose removal would reduce dependence on a sweetener that has limited functional value in a swallowed tablet. A sucrose-free product may also be easier to position for patients who require chronic treatment.

This path has the lowest technical risk and could support an ANDA if the finished product meets applicable sameness requirements for strength, dosage form, route, and performance.

Pediatric-friendly hydrocortisone formulation

The most attractive unmet need is a formulation for children with adrenal insufficiency. Potential dosage forms include:

• Mini-tablets
• Orodispersible tablets
• Taste-masked granules
• Oral suspension
• Dispersible tablets
• Multiparticulates in capsules or sachets

A pediatric product could improve dose titration and administration during infancy and early childhood. The formulation would need robust dose uniformity at low drug load, acceptable taste, chemical stability in water or food vehicles, and clear instructions for dose preparation.

An oral liquid would create a larger excipient and manufacturing burden than a tablet. It would require control of sedimentation, microbial growth, preservative performance, viscosity, dosing-device accuracy, and in-use stability. A dry suspension or dispersible tablet could reduce some of those risks while retaining pediatric utility.

Scored and low-dose-flexibility tablets

A 5 mg tablet with a reliable score line can support fractional dosing. A 10 mg or 20 mg tablet may provide manufacturing and packaging efficiency but may not address the clinical need for small dose adjustments.

A differentiated product could combine:

• A 5 mg scored tablet
• A 10 mg scored tablet
• A 20 mg tablet for adult replacement regimens
• Packaging with dose calendars or administration instructions

Under FDA guidance, a scored tablet must demonstrate that the divided portions meet relevant specifications for mass, assay, and content uniformity. A score-line claim without supporting data would not provide a durable commercial advantage. (FDA, 2013)

Excipient-minimized formulation

An excipient-minimized tablet could target patients who report intolerance to lactose, sucrose, dyes, or preservatives. A formulation based on microcrystalline cellulose, starch, and a conventional lubricant could be marketed with a transparent inactive-ingredient profile.

The commercial value would depend on credible differentiation. A shorter excipient list alone is unlikely to support significant pricing power unless it is tied to a documented patient segment, specialty-distribution strategy, or clinician preference.

What patents protect CORTEF and hydrocortisone tablets?

The historical CORTEF product is not protected by a commercially meaningful active-ingredient patent estate. Hydrocortisone was discovered and used clinically decades ago. Any original patents covering the active compound or basic oral tablet technology have expired.

IP category	CORTEF position	Commercial implication
Active ingredient patent	Expired	No composition-of-matter barrier
Historical immediate-release tablet patents	Expired or commercially immaterial	Conventional generic replication is possible
Formulation patents	No material public barrier associated with the legacy product identified	New formulation patents would need specific technical claims
Method-of-use patents	Legacy indications are old and broadly established	Limited leverage against standard generic use
Manufacturing know-how	Potentially confidential	May affect quality and supply but is not equivalent to patent exclusivity
Trademark	CORTEF brand rights may remain jurisdiction-specific	Brand recognition can support switching resistance but does not block generics

A new excipient strategy could support patent filings if it produces a technically defined and clinically relevant result. Potential claim categories include:

• Specific excipient ratios
• Low-dose content-uniformity systems
• Taste-masked hydrocortisone granules
• Stable oral suspensions
• Pediatric multiparticulate dosage forms
• Improved tablet splitting
• Enhanced dissolution under defined conditions
• Packaging systems that improve moisture protection or dose administration

A patent application based only on replacing lactose with another filler would face obviousness risk unless the formulation produces an unexpected stability, dissolution, manufacturability, or patient-use result.

When does CORTEF lose exclusivity and what is the FDA regulatory status?

CORTEF's meaningful regulatory exclusivity has expired. Hydrocortisone tablets are eligible for generic competition through the abbreviated new drug application pathway, assuming the reference product and relevant FDA listing requirements are satisfied.

What is the Orange Book status of CORTEF?

The Orange Book is the primary FDA source for approved drug products, therapeutic equivalence evaluations, patents, and exclusivity information. Legacy brand status can change over time depending on marketing status, manufacturer activity, and FDA administrative records. A company evaluating CORTEF should distinguish among:

1. The historical CORTEF NDA.
2. Current marketed hydrocortisone reference products.
3. Generic hydrocortisone tablets with therapeutic-equivalence codes.
4. Discontinued or withdrawn listings.
5. Any active Orange Book patent or exclusivity record.

For a standard hydrocortisone tablet, the practical regulatory pathway is generally an ANDA referencing an approved product. A reformulated product with a different dosage form, route, strength, or clinically meaningful formulation change may require a new NDA or a 505(b)(2) application rather than a conventional ANDA. (FDA, n.d.-b)

Are Paragraph IV challenges relevant to CORTEF?

Paragraph IV litigation risk is limited where the target product has no active Orange Book-listed patents. A generic applicant may still file a patent certification as required by the ANDA process, but the commercial significance depends on whether any enforceable listed patents remain.

The larger risk is product-specific regulatory delay, not patent litigation. A developer may face:

• Reference-product selection issues
• Bioequivalence failures
• Inadequate dissolution discrimination
• Tablet-splitting deficiencies
• Stability failures
• Incomplete labeling equivalence
• Manufacturing-site inspection findings

What formulation patents could create commercial value?

A new hydrocortisone product can generate stronger IP if the formulation solves a defined clinical or manufacturing problem.

Pediatric formulation patents

Pediatric patents could claim a stable, palatable, low-dose formulation that delivers accurate hydrocortisone quantities after dispersion or administration with food. Useful claim features may include particle engineering, polymeric taste masking, granule size, release profile, and storage conditions.

A pediatric formulation would also benefit from clinical or usability data. Patent protection without evidence of dose accuracy and acceptable administration would have limited commercial force.

Modified-release hydrocortisone patents

Modified-release hydrocortisone products seek to approximate the circadian cortisol profile. These products can command greater commercial value than conventional immediate-release tablets, but they require more extensive clinical development.

Potential platforms include:

• Delayed-release tablets
• Pulsatile-release systems
• Dual-release tablets
• Chronotherapeutic multiparticulates

The patent estate would need to cover the release mechanism, pharmacokinetic profile, formulation architecture, and potentially dosing regimen. Method-of-use patents may be valuable if the product demonstrates improved control of symptoms, sleep, metabolic parameters, or quality of life.

Oral-liquid and suspension patents

An oral liquid could be protected through claims directed to:

• Hydrocortisone particle size
• Suspending-agent concentration
• Preservative system
• In-use stability
• Dose-delivery device
• Reconstitution or dilution instructions

Regulatory claims must match the formulation. A product that is chemically stable in the bottle but loses uniformity after shaking or during repeated dosing would have weak commercial utility.

What generic entry risks exist for CORTEF?

Generic entry risk is high for conventional hydrocortisone tablets because:

• The active ingredient is off-patent.
• The dosage form is technically conventional.
• The excipients are common pharmaceutical materials.
• Treatment is established across multiple indications.
• Substitution is generally feasible where state pharmacy rules and product labeling permit it.
• Manufacturing can be performed by numerous contract and vertically integrated suppliers.

The strongest barriers are operational rather than legal. A competitor with reliable supply, accurate low-dose manufacturing, and broad distribution can enter without developing a complex delivery system.

How would generic manufacturers compete?

Competition is likely to focus on:

• Lowest acquisition cost
• Reliable supply of 5 mg, 10 mg, and 20 mg strengths
• Therapeutic-equivalence ratings
• Wholesale distribution
• Hospital and specialty-pharmacy contracts
• Pediatric formulation extensions
• Rebate and formulary placement
• Shortage avoidance

A conventional generic manufacturer would have limited incentive to invest heavily in differentiated excipients unless a shortage, supplier problem, or specialty-market opportunity supports higher margins.

What commercial opportunities exist for a new CORTEF formulation?

The best opportunities are segmented by patient need rather than by broad adult corticosteroid use.

Product concept	Patient segment	Development burden	Pricing potential	IP potential
Lactose-free tablet	Patients with excipient intolerance	Low	Low to moderate	Low
Sucrose-free tablet	Chronic-use patients and dietary-sensitive populations	Low	Low to moderate	Low
Highly divisible 5 mg tablet	Adrenal insufficiency patients requiring dose titration	Low to moderate	Moderate	Moderate
Mini-tablet or dispersible tablet	Infants and young children	Moderate	Moderate to high	Moderate to high
Taste-masked granules	Pediatric and swallowing-limited patients	Moderate	High	High
Oral suspension	Pediatric patients and feeding-tube users	Moderate to high	Moderate to high	Moderate
Modified-release product	Patients needing circadian replacement	High	High	High
Combination or packaged stress-dose system	Patients managing adrenal crises	Moderate	Moderate to high	Moderate

Revenue exposure and market sizing

Public filings generally do not report CORTEF-specific revenue separately from broader corticosteroid portfolios. Product-level revenue exposure should therefore be assessed through prescription volume, average selling price, payer mix, generic substitution, shortage history, and channel concentration rather than through a standalone brand-revenue figure.

The largest addressable commercial segment is standard hydrocortisone replacement. It is also the most price-sensitive and exposed to generic substitution. Specialty value is more likely in:

• Pediatric adrenal insufficiency
• Patients requiring feeding-tube administration
• Patients unable to swallow conventional tablets
• Patients with excipient intolerance
• Patients needing precise low-dose titration
• Patients requiring a circadian or modified-release profile

How does CORTEF compare with competing hydrocortisone products?

Attribute	CORTEF legacy tablet	Generic hydrocortisone tablet	Differentiated pediatric product	Modified-release hydrocortisone
Dosage form	Immediate-release tablet	Immediate-release tablet	Liquid, granule, mini-tablet, or dispersible tablet	Extended or delayed release
Excipients	Conventional, includes lactose and sucrose in labeled formulation	Varies by manufacturer	Optimized for taste, stability, and dosing	Functional polymers and release-control excipients
Patent strength	Low	Low	Potentially moderate to high	Potentially high
Regulatory pathway	Legacy NDA	ANDA	ANDA, 505(b)(2), or NDA depending on change	Usually 505(b)(2) or NDA
Generic substitution risk	High	High	Lower if dosage form is differentiated	Lower if clinically differentiated
Pediatric suitability	Limited	Variable	High	Variable
Pricing power	Low to moderate	Low	Moderate to high	High if clinical benefit is shown

What manufacturing and IP barriers affect a CORTEF opportunity?

Manufacturing barriers are manageable for conventional tablets but increase sharply for pediatric and modified-release products.

Key controls include:

• Hydrocortisone assay and content uniformity
• API particle-size distribution
• Blend uniformity at low drug load
• Tablet hardness and friability
• Score-line performance
• Dissolution across pH conditions
• Moisture and light protection
• Excipient compatibility
• Microbial control for liquids
• In-use stability after opening or reconstitution
• Device accuracy for oral syringes or dosing cups

Geographic coverage should be planned across the United States, European Union, United Kingdom, Japan, Canada, and major emerging markets. Patentability, pediatric labeling requirements, reference-product availability, and substitution rules differ by jurisdiction. A formulation patent filed only in the United States will not protect commercial entry in Europe or Asia.

Manufacturing know-how can complement patents. Supplier qualification for hydrocortisone API, specialized taste-masking materials, and pediatric dosing devices may create practical barriers, but these barriers remain vulnerable to second sourcing and process replication.

What licensing deals or settlement agreements affect CORTEF?

No commercially material licensing structure or patent settlement is inherent in the legacy CORTEF tablet. Conventional hydrocortisone tablets are generally accessible through generic development without a branded formulation license.

Licensing opportunities would be more relevant for:

• Modified-release hydrocortisone technology
• Pediatric taste-masking platforms
• Multiparticulate manufacturing
• Oral-liquid preservation systems
• Precision dosing devices
• Circadian cortisol-replacement technology

A developer should evaluate freedom to operate separately for the active ingredient, dosage form, excipient combination, manufacturing process, delivery device, and method of treatment. A formulation license may not provide freedom to market if a device or method patent remains active in the target jurisdiction.

Key Takeaways

• CORTEF is a conventional immediate-release hydrocortisone tablet with a simple excipient system.
• FDA labeling identifies lactose, mineral oil, sorbic acid, starch, and sucrose as inactive ingredients.
• The legacy product has no meaningful remaining active-ingredient patent exclusivity.
• Generic entry risk is high for standard hydrocortisone tablets.
• The strongest commercial opportunity is a pediatric product with accurate low-dose delivery and improved palatability.
• Lactose-free, sucrose-free, and highly divisible tablets are lower-risk extensions but have weaker IP and pricing potential.
• Modified-release hydrocortisone offers greater differentiation but requires substantially more clinical and regulatory investment.
• Manufacturing reliability, content uniformity, tablet splitting, and pediatric usability are more important barriers than legacy CORTEF patents.
• No biosimilar pathway applies because hydrocortisone is a small-molecule drug, not a biologic.
• Any investment case should prioritize differentiated dosage forms, specialty distribution, and formulation-specific patent claims.

FAQs About CORTEF Excipients and Commercial Strategy

Does CORTEF contain lactose?

FDA labeling identifies lactose among the inactive ingredients in CORTEF tablets. A lactose-free competitor could target patients with lactose intolerance or excipient sensitivity.

Is CORTEF gluten-free?

The presence or absence of gluten cannot be established solely from the ingredient list. Gluten status depends on excipient sourcing, manufacturing controls, cross-contamination controls, and manufacturer certification.

Can a company make a generic version of CORTEF?

Yes. Hydrocortisone tablets are eligible for generic development through the ANDA pathway when the proposed product meets applicable requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling.

Is there a biosimilar version of CORTEF?

No. Hydrocortisone is a small-molecule active pharmaceutical ingredient. Competing products are regulated as generic drugs or, for differentiated formulations, potentially under the 505(b)(2) or NDA pathways.

Which CORTEF reformulation has the highest commercial potential?

A pediatric hydrocortisone formulation with accurate low-dose administration, acceptable taste, and stable performance has the strongest differentiation potential. A modified-release product may have greater pricing power but requires materially higher development risk and clinical investment.

References

1. U.S. Food and Drug Administration. (n.d.-a). CORTEF (hydrocortisone) tablets prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2013). Tablet scoring: Guidance for industry. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.

5. National Library of Medicine. (n.d.). Hydrocortisone drug labeling and product information. DailyMed.